Actelion has announced its financial results for the first nine months of 2009, with total net revenues of CHF1,302.5m and operating expenses of CHF939.3m. The company reported an operating profit of CHF363.2m.
For the first nine months of 2009, Actelion reported a Cash EBIT of CHF462.0m, an increase of 30% compared to the same period in 2008. Adjusted (non-US GAAP) diluted earnings per share for the first nine months of 2009 were CHF3.48, compared to CHF2.53 during the same period last year.
On a US GAAP basis, net profit for the first nine months of 2009 was CHF326.9m. Fully diluted earnings per share (EPS) on a US GAAP basis for the same period were CHF2.66, compared to CHF1.84 for the first nine months of 2008.
Jean-Paul Clozel, MD and chief executive officer of Actelion, said: “Actelion continues to execute in-line with its strategy to create long-term value for patients. Our franchise in pulmonary arterial hypertension will ensure profitable growth going forward. With two additional promising PAH compounds in advanced clinical development which include macitentan and our partnership with Nippon Shinyaku to develop the PGI2 receptor agonist, we intend to remain on the forefront of PAH research and therapy.”
Andrew Oakley, chief financial officer of Actelion, said: “In the first nine months of 2009, Actelion’s base business is continuing to perform strongly, despite an adverse currency environment that especially impacted Q3 performance as expressed in our reporting currency, the Swiss Franc. In July of this year, Actelion upgraded guidance for FY 2009 of both top-line and Cash EBIT growth between 16 and 19 percent in local currencies. Today, I can confirm guidance and I forecast that we will very likely be towards the upper end of the ranges given.”